Congenital Hyperinsulinism Treatment Market Size, Share, Trends and Forecast 2026-2035

Congenital Hyperinsulinism Treatment Market Size and Overview

The congenital hyperinsulinism treatment market reached US$171.9 Million in 2025 and is expected to reach US$293.6 Million by 2035, growing with a CAGR of  5.5% during the forecast period 2026-2035.

Current treatment remains centered on diazoxide, somatostatin analogues, nutritional management and pancreatic surgery for severe or treatment-refractory cases. However, the competitive landscape is shifting toward targeted and longer-acting therapies designed to improve glycemic control and reduce dependence on invasive interventions.

Companies such as Zealand Pharma, Rezolute and Hanmi Pharmaceutical are advancing next-generation CHI therapies, while growing adoption of genetic testing is improving differentiation between focal and diffuse disease. North America remains a key regional market due to specialized pediatric endocrinology centers, clinical trial activity and stronger access to emerging rare-disease treatments.

Congenital Hyperinsulinism Treatment Market Key Takeaways

• The global congenital hyperinsulinism treatment market was valued at approximately USD 171.9 million in 2025 and is projected to reach about USD 293.6 million by 2035, expanding at a CAGR of 5.5% during 2026-2035.
• Treatment innovation is shifting beyond conventional diazoxide therapy, with companies such as Zealand Pharma, Rezolute and Hanmi Pharmaceutical developing CHI-specific therapies aimed at improving glucose control in severe and diazoxide-unresponsive patients.
• Genetic testing is becoming increasingly important in treatment selection, particularly for identifying ABCC8, KCNJ11 and other CHI-associated mutations that can help distinguish focal and diffuse disease and guide medical or surgical management.
• North America remains the leading regional market, supported by advanced pediatric endocrinology centers, strong rare-disease research activity, clinical trial participation and relatively early access to emerging therapies.
• Major unmet needs remain in severe and treatment-resistant CHI, creating opportunities for long-acting glucagon analogues, insulin-receptor-targeting therapies, wearable drug-delivery systems, continuous glucose monitoring integration and home-based disease-management solutions.

Congenital Hyperinsulinism Treatment Market Scope

Congenital Hyperinsulinism Treatment Market White Space & Investment Opportunities

• Next-Generation Therapies for Diazoxide-Unresponsive CHI:

  Invest in targeted therapies capable of controlling persistent hypoglycemia in patients who respond inadequately to diazoxide, particularly those with severe K ATP channel-related congenital hyperinsulinism. Opportunities are attractive for long-acting glucagon analogues, insulin-receptor-targeting therapies and other disease-specific approaches that can reduce dependence on continuous feeding, intravenous glucose and pancreatic surgery. Therapies offering sustained glucose control, convenient subcutaneous administration and improved pediatric tolerability could address one of the largest unmet needs in CHI management.

• Genotype-Guided Precision Treatment and Diagnostic Platforms:

  Develop rapid genetic testing, next-generation sequencing and integrated diagnostic platforms capable of identifying ABCC8, KCNJ11, GCK, GLUD1, HADH and other CHI-associated variants. Faster molecular diagnosis can improve differentiation between focal and diffuse disease, guide treatment selection and support timely referral for specialized imaging or surgery. Investment opportunities also exist in companion diagnostic tools that can stratify patients for emerging targeted therapies and clinical trials.

• Home-Based and Continuous Glucose Management Solutions:

  Expand investment in wearable drug-delivery systems, continuous glucose monitoring integration and home-based treatment platforms designed specifically for infants and children with congenital hyperinsulinism. Technologies combining continuous glucose data with automated or programmable delivery of glucagon-based therapies could reduce hospital dependence and improve day-to-day disease management. Solutions that lower caregiver burden, simplify dosing and provide early warning of hypoglycemic events represent an important white-space opportunity as CHI treatment increasingly shifts toward long-term outpatient and home-based care.

Congenital Hyperinsulinism Treatment Market Buyer Decision-Making Criteria

Major Buyer Decision-Making Criteria:

• Reduction in Hypoglycemic Events
• Ability to Maintain Target Glucose Levels
• Response in Diazoxide-Unresponsive Patients
• Durability of Glycemic Control
• Safety and Tolerability Profile
• Reduction in Need for Continuous Feeding or Intravenous Glucose
• Convenience of Dosing and Route of Administration
• Compatibility With Existing CHI Therapies
• Suitability by Genetic and Disease Subtype
• Ability to Reduce or Avoid Pancreatic Surgery
• Pediatric Age-Group Suitability
• Long-Term Treatment Burden
• Regulatory Approval and Clinical Evidence
• Reimbursement and Treatment Cost
• Availability Through Specialized Treatment Centers

Congenital Hyperinsulinism Treatment Market BCG Matrix: Company Evaluation 

STAR

Zealand Pharma can be positioned in the Star category of the congenital hyperinsulinism treatment market because its dasiglucagon program is among the most advanced CHI-specific development programs. Dasiglucagon is designed for continuous subcutaneous infusion through a wearable pump, addressing the need for sustained glucose control in infants and children with CHI. The therapy has been evaluated across three Phase 3 studies, and its use for up to three weeks is currently under FDA review, with a further submission planned for longer-duration treatment. Zealand Pharma’s late-stage regulatory position and differentiated delivery approach strengthen its potential competitive position in CHI treatment.

POTENTIAL

Rezolute, Hanmi Pharmaceutical and Amylyx Pharmaceuticals represent the Potential category, supported by differentiated mechanisms and ongoing clinical-development opportunities. Rezolute is advancing ersodetug, an insulin-receptor-modulating monoclonal antibody; although its Phase 3 sunRIZE trial did not meet the primary endpoint, additional data remain under FDA review. Hanmi Pharmaceutical is progressing once-weekly efpegerglucagon, with the core treatment period of its global Phase 2 ACHIEVE study completed in 2026. Amylyx Pharmaceuticals is evaluating avexitide for congenital hyperinsulinism following earlier clinical studies. Collectively, these companies could expand treatment choice if ongoing development demonstrates clinically meaningful glucose control, durable efficacy and acceptable safety.

Congenital Hyperinsulinism Treatment Market Dynamics       

Driver Impact Analysis

Driver: Growing Development of CHI-Specific Therapies

The growing development of targeted therapies for congenital hyperinsulinism is expected to drive market growth by addressing limitations of conventional treatments such as diazoxide and surgery. Zealand Pharma is advancing continuous-infusion dasiglucagon, which is currently at the registration stage and under FDA review for treatment of CHI for up to three weeks. Hanmi Pharmaceutical is developing once-weekly efpegerglucagon, which received FDA Breakthrough Therapy Designation in February 2026, while its global Phase 2 ACHIEVE study progressed during 2026. These programs are expanding the therapeutic pipeline and supporting demand for more convenient, disease-focused treatment options.

Restraint Impact Analysis

Restraint: Limited Effectiveness of Diazoxide in Severe CHI

Diazoxide remains the principal first-line pharmacological treatment for congenital hyperinsulinism, but its effectiveness is limited in a significant proportion of patients with severe disease, particularly those with inactivating K ATP channel mutations involving ABCC8 or KCNJ11. Poor response can result in persistent hypoglycemia and a continued need for frequent glucose monitoring, intensive nutritional support, second-line therapies and, in selected cases, pancreatic surgery. This therapeutic limitation increases treatment complexity, prolongs hospital management and creates demand for more effective CHI-specific therapies capable of achieving sustained glucose control while reducing dependence on invasive interventions.

Congenital Hyperinsulinism Treatment Market Geographical Penetration

U.S. Congenital Hyperinsulinism Treatment Market Landscape

The United States congenital hyperinsulinism treatment market is characterized by highly specialized pediatric care, advanced genetic diagnosis and substantial late-stage drug-development activity. CDC provisional data released in April 2026 recorded 3,606,400 U.S. births in 2025. CHOP estimates congenital hyperinsulinism occurs in roughly 1 in 25,000-50,000 births; applying this incidence range to 2025 births indicates an illustrative annual pool of approximately 72-144 affected newborns, although this is an analytical estimate rather than an official diagnosed-patient count. Treatment remains centered on maintaining safe glucose levels through medical therapy, nutritional management and surgery for refractory disease, supported by specialized centers such as CHOP. The innovation environment accelerated during 2026. Hanmi Pharmaceutical reported that the FDA granted Breakthrough Therapy Designation to once-weekly efpegerglucagon in February 2026. Zealand Pharma's continuous-infusion dasiglucagon is at the registration stage, with the portion of its NDA covering treatment for up to three weeks under FDA review. Rezolute also continued regulatory discussions with the FDA around Phase 3 sunRIZE data for ersodetug during 2026. These developments are shifting the U.S. market toward CHI-specific, longer-duration and more convenient therapies.

Japan Congenital Hyperinsulinism Treatment Market Outlook

The Japan congenital hyperinsulinism treatment market remains a highly specialized rare-disease segment centered on neonatal diagnosis, diazoxide therapy, genetic testing and management through pediatric endocrinology centers. Japan's Ministry of Health, Labour and Welfare monthly vital-statistics data indicate approximately 671,236 births during 2025 based on the reported monthly totals. Previous nationwide Japanese surveillance estimated the incidence of transient CHI at approximately 1 in 13,600 births and persistent CHI at 1 in 31,600 births. Applying these historical incidence rates to 2025 births would imply roughly 49 transient and 21 persistent cases annually, or around 70 potential new cases, although this is an analyst-derived estimate rather than a reported 2025 diagnosis count. Japanese research activity continued during 2025, with investigators reporting a rare KCNJ11 readthrough variant associated with CHI, reinforcing the importance of molecular diagnosis and genotype-based disease characterization. Another 2025 Japanese clinical publication examined management of diazoxide-induced pulmonary hypertension, highlighting the need for careful safety monitoring during established therapy. Overall, Japan offers opportunities for improved genetic diagnostics, safer long-term medical management and next-generation CHI-specific therapies capable of reducing dependence on diazoxide, continuous nutritional support and pancreatic surgery.

Congenital Hyperinsulinism Treatment Market Competitive Landscape

• The global congenital hyperinsulinism treatment market has a relatively concentrated innovation landscape, while commercialization of established therapies is spread across specialty pharmaceutical and generic drug manufacturers. Current treatment continues to rely heavily on diazoxide, supported by somatostatin analogues, glucagon-based approaches and surgical intervention for treatment-refractory patients. PROGLYCEM, marketed by Teva Pharmaceuticals in the United States, is indicated for hypoglycemia associated with hyperinsulinism in infants, children and adults.
• Competition is increasingly shifting toward disease-focused therapies designed to provide more consistent glucose control and reduce dependence on existing standard-of-care treatments. Zealand Pharma is advancing continuous-infusion dasiglucagon, which is currently at the registration stage, with part of its U.S. NDA under FDA review. The therapy combines a glucagon analogue with a wearable continuous-infusion system.
• Rezolute is developing ersodetug, an insulin-receptor-targeting monoclonal antibody. Its Phase 3 sunRIZE study was completed, although the primary endpoint was not met, and the company reported in September 2026 that the data remained under FDA review. Hanmi Pharmaceutical is developing once-weekly efpegerglucagon and completed the core treatment period of its global Phase 2 study in 2026. Amylyx Pharmaceuticals is also evaluating development opportunities for avexitide in congenital hyperinsulinism following earlier clinical studies.
• Overall, competitive differentiation is moving toward longer-acting therapies, reduced hypoglycemic episodes, convenient subcutaneous administration, continuous glucose control and reduced treatment burden, creating opportunities for rare-disease biotechnology companies alongside established pharmaceutical manufacturers.

Key Companies of Congenital Hyperinsulinism Treatment Market 

• Zealand Pharma A/S (Denmark)
• Rezolute, Inc. (United States)
• Hanmi Pharmaceutical Co., Ltd. (South Korea)
• Amylyx Pharmaceuticals, Inc. (United States)
• Crinetics Pharmaceuticals, Inc. (United States)
• Xeris Biopharma Holdings, Inc. (United States)
• Novartis AG (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Endo, Inc. (United States)
• Novo Nordisk A/S (Denmark)
• Merck & Co., Inc. (United States)
• Bayer AG (Germany)
• Fresenius SE & Co. KGaA (Germany)
• Viatris Inc. (United States)
• Sun Pharmaceutical Industries Limited (India)
• Amphastar Pharmaceuticals, Inc. (United States)
• Glenmark Pharmaceuticals Limited (India)
• Hainan Shuangcheng Pharmaceuticals Co., Ltd. (China)
• USV Private Limited (India)
• e5 Pharma, LLC (United States)

Congenital Hyperinsulinism Treatment Market Recent Developments

• September 2026: Rezolute reported that the U.S. FDA was continuing its review of additional Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism. The company submitted additional datasets and analyses emphasizing continuous glucose monitoring outcomes, while the open-label extension continued to show indicators of improved glycemic control and reduced use of background standard-of-care therapies.
• September 2026: Hanmi Pharmaceutical announced that the core treatment period of the global Phase 2 ACHIEVE study of efpegerglucagon (HM15136) in congenital hyperinsulinism had been completed and the clinical data were under analysis. Hanmi presented the program at the European Society for Paediatric Endocrinology 2026 meeting; efpegerglucagon is being developed as a once-weekly glucagon analogue for CHI.
• August 2026: Zealand Pharma reported that it expected to resubmit the New Drug Application for dasiglucagon in congenital hyperinsulinism to the U.S. FDA during the second half of 2026. The planned submission is intended to cover both treatment for up to three weeks and use beyond three weeks.
• June 2026: Rezolute presented additional analyses from its ersodetug clinical program at ENDO 2026, including data from the Phase 3 sunRIZE study in congenital hyperinsulinism and analyses examining the disease's neurological and health-economic burden. The company highlighted CGM-based analyses supporting continued investigation of ersodetug for refractory hypoglycemia associated with congenital hyperinsulinism.

What DATAM Uniquely Provides

• In-depth segmentation of the Congenital Hyperinsulinism Treatment Market by disease type, drug type, route of administration, distribution channel and region, with additional assessment of K ATP-hyperinsulinism, GDH-hyperinsulinism, GK-hyperinsulinism, SCHAD-hyperinsulinism, UCP2-hyperinsulinism, HNF4A and HNF1A-hyperinsulinism and MCT1-hyperinsulinism.
• Competitive analysis of leading congenital hyperinsulinism treatment companies covering marketed and pipeline product portfolios, mechanism of action, clinical efficacy, dosing approach, safety profile, route of administration, regulatory status, clinical-development stage, commercialization strategy and geographic expansion, including companies such as Zealand Pharma, Rezolute, Hanmi Pharmaceutical, Amylyx Pharmaceuticals, Teva Pharmaceutical Industries and Novartis.
• Comprehensive assessment of diagnosed and treatable congenital hyperinsulinism patient populations, including analysis by genetic subtype, focal versus diffuse disease, diazoxide responsiveness, severity of hypoglycemia, age group, treatment history and eligibility for medical therapy, investigational therapies or pancreatic surgery, supporting evaluation of addressable patient pools and unmet treatment needs.